Last updated on April 18, 2014 at 12:30 EDT

Menarini Group and Oxford BioTherapeutics Sign Major Strategic Collaboration for the Clinical Development and Manufacture of a Portfolio of Novel Antibody-Based Cancer Drugs

October 29, 2012

OXFORD, England and FLORENCE, Italy, October 29, 2012 /PRNewswire/ –

Menarini and Oxford BioTherapeutics (OBT) today announce a major innovative and
strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.
The agreement covers five of OBT’s antibody and antibody drug conjugate (ADC) programs,
each of which addresses a different cancer indication via a different novel oncology
target. The deal brings together OBT’s discovery expertise with Menarini’s clinical
knowledge, and expanding capabilities in the manufacture and development of biologics, to
build value for both companies as they work to bring this exciting portfolio of next
generation antibody-based cancer drugs to market.

Under the collaboration, Menarini will lead the efforts in the manufacture and
clinical development of each program, supported by OBT, while OBT will provide the
proprietary cancer target, antibody and arming technologies.

Once clinical proof of concept has been achieved, OBT will complete the clinical
development and commercialise these novel antibody-based products in North America and
Japan, whilst Menarini will develop and commercialise the products in Europe, CIS, Asia
and Latin America.

Christian Rohlff, CEO of OBT, commented, “I am delighted to collaborate with Menarini,
a company that has made impressive achievements in biologics development and demonstrated
an enduring commitment to the development of innovative cancer therapies. This creative
alliance is transformational for us as it allows OBT to participate in the clinical
development and future commercialisation of our programs while at the same time it
bolsters Menarini’s pipeline with a portfolio of the next generation of cancer drugs. We
believe this innovative business framework could become the business model of choice for
rapidly growing biotechnology companies seeking new ways to develop their drug pipeline

Alberto Giovanni Aleotti, member of the Board of A. Menarini, commented, “We are eager
to start our collaboration with OBT, an oncology company with a proven track record of
generating innovative antibody-based cancer drug candidates that are designed to address
high unmet medical needs. I am very pleased that this novel strategic alliance, which
foresees the development and manufacture of up to 5 cancer treatment programs and a total
investment of 800 million Euro, will enable us to further demonstrate our deep and long
standing commitment to the fight against cancer, which has always been crucial to
Menarini’s overall corporate mission.”

OBT’s dedicated development operation in Basel, Switzerland, established in May 2012
under the direction of COO Dr. Esteban Pombo, will perform a central role in supporting
the new collaboration as OBT and Menarini work together to progress OBT’s most advanced
therapeutic antibody and antibody drug conjugate (ADC) oncology programs into clinical

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused
on delivering innovative and cost-effective first-in-class medicines to fulfil major unmet
patient needs in the field of cancer. OBT is developing cutting-edge antibody-based cancer
medicines, with integrated diagnostics, against novel targets that it has discovered
through its unique OGAP(R) proteomic database. OBT has access to the most advanced
antibody technologies and expertise through its partnerships with many of the world
leaders in antibody development, including Seattle Genetics, BMS (Medarex), Amgen, Alere
(formerly Biosite) and BioWa, and through its development alliances with GlaxoSmithKline
and Sanofi. OBT’s diagnostic collaboration with Alere also provides the opportunity to
develop tailored diagnostics for OBT’s therapeutic products. These partnerships have
enabled OBT to convert its world-leading capabilities in the discovery of novel oncology
targets into a highly attractive pipeline of therapeutic antibodies.

For further information, please see http://www.oxfordbiotherapeutics.com

About Menarini Group

Menarini is an international pharmaceutical company which, with a 2011 consolidated
worldwide turnover of more than 3 billion Euro, ranks 17th in Europe and 34th world-wide.

Menarini’s territorial presence covers more than 100 countries in Europe, Africa,
Asia, Australia and Latin America, with 15,000 headcount. Menarini was founded 125 years
ago and currently markets products for the most important therapeutic fields: respiratory,
cardiovascular, gastroenterology, oncology, metabolism, antibiotics, diabetes,
anti-inflammatories and analgesics. The Menarini Group has always pursued two strategic
objectives: Research and Internationalisation, both of which have allowed it to achieve
outstanding results in today’s global market and invest in the research of innovative
drugs, making them available to patients all around the world.

For further details, please see http://www.menarini.com.

OBT Contact Information:

        Chief Executive Officer:
        Christian Rohlff, Ph.D.

        Media enquiries/Citigate:
        David Dible
        Menarini Group Contact Information:
        Menarini Press Office:
        Valeria Speroni Cardi

SOURCE Oxford BioTherapeutics and Menarini

Source: PR Newswire